| Literature DB >> 20217610 |
Alexander Gaitanis1, Stephen Staal.
Abstract
Liposomal doxorubicin and nab-paclitaxel are nanoparticle formulations of traditional cancer chemotherapy drugs which have ample clinical experience both pre- and post-nanoparticle modification. The alterations in pharmacokinetics, pharmacodynamics, efficacy, and toxicity compared with their parent compounds are instructive for future development of nanoparticle-based therapies. In this article we review the current status of these agents, emphasizing the alterations in clinical behavior resulting from the nanoparticle formulation of the parent compound.Entities:
Mesh：
Substances：
Year: 2010 PMID： 20217610 DOI： 10.1007/978-1-60761-609-2_26
Source DB: PubMed Journal: Methods Mol Biol ISSN： 1064-3745